Skip to main content

Dr. Chundawat to lead NIIMBL biomanufacturing team

Rutgers team, led by PI Chundawat, has been selected by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) as part of the Institute’s Project Call 5.2. Chundawat-led team will develop and validate an integrated process analytical technology (PAT) to automate continuous monitoring of critical drug quality attributes like N-glycosylation during upstream biomanufacturing of therapeutic proteins like monoclonal antibodies. The research project is titled “An Integrated Platform for Fully Automated, Continuous, & Real-Time Multi-Attributes Monitoring of Upstream Processes for Glycosylated Monoclonal Antibodies Production”. Other project participants include Agilent Technologies, Endress+Hauser, and University of Delaware. The summary can be read in the Press Release via the following link: Link

The $1.5 million project cost includes $750k research grant from NIIMBL with remainder in-kind support including donated equipment/supplies & other cost-share support from industry and university partners. The project, part of 14 new projects sponsored by NIIMBL, will be completed over a 18 month period starting in April 2023.